Core Viewpoint - Walgreens is nearing a $10 billion deal to go private, which has resulted in an increase in its stock price [1] Group 1: Company Overview - The potential deal indicates a significant shift in Walgreens' strategy, moving towards privatization [1] - The stock price of Walgreens has risen in response to the news of the impending deal [1] Group 2: Financial Implications - The deal is valued at approximately $10 billion, highlighting the scale of the transaction [1] - The privatization could lead to changes in operational focus and financial restructuring for Walgreens [1]

Group 1 - Walgreens Boots Alliance Inc. is nearing a $10 billion deal to sell itself to Sycamore Partners, a private-equity firm [1] - The deal would result in Walgreens being taken private and likely broken up [1] - The potential announcement of the deal could occur as soon as Thursday [1]

Group 1: Logitech International SA (LOGI) - LOGI shares are down 2.9%, trading at $98.24, following a downgrade to "underperform" from "neutral" by BofA Global Research due to recent struggles and tariff threats [1][2] - The stock recently attempted to break its three-year high of $105.65 but closed below its 20-day moving average for the first time since January, despite an 18.8% increase so far in 2025 [2] - Options traders are showing bullish sentiment with a 50-day call/put volume ratio of 31.05, which is higher than 98% of annual readings [3] Group 2: Walgreens Boots Alliance Inc (WBA) - WBA shares are down 3.8%, trading at $10.81, following a downgrade to "sell" from "hold" by Deutsche Bank due to high uncertainty, and the stock has a year-over-year deficit of 49.7% [1][3] - Despite a 15.5% year-to-date gain, WBA has faced overhead pressure at the $12 level, capping rallies since late January [3] - Options activity is notably bullish, with 28,000 calls traded, which is double the intraday average volume, compared to only 5,051 puts [4]

Walgreens Boots Alliance (WBA) ended the recent trading session at $11.23, demonstrating a +1.72% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 1.59% for the day. Elsewhere, the Dow saw a downswing of 0.45%, while the tech-heavy Nasdaq depreciated by 2.78%.Prior to today's trading, shares of the largest U.S. drugstore chain had lost 1.87% over the past month. This has lagged the Retail-Wholesale sector's gain of 0.87% and was narrower than the S&P 5 ...

Shares of Walgreens Boots Alliance (WBA 1.72%) rose on Thursday, up as much as 7.3% before settling into a 2.2% gain by 3:30 p.m. ET. That gain was still notable, since the broader markets were down significantly on the day.News reports circulated with further details on a potential buyout of the company by private equity firm Sycamore Partners, which has been in talks to buy the troubled pharmacy since late 2024.A potential three-way splitAccording to people familiar with the matter and reported in the Fin ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by March 31, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [4] Group 3: Case Allegations - The lawsuit alleges that Walgreens failed to disclose widespread violations of federal law regarding prescription medication dispensation and reimbursement during the Class Period [5] - It is claimed that Walgreens' conduct posed a risk of regulatory scrutiny, civil liability, and reputational harm, and that its revenue from prescription sales was unsustainable due to unlawful practices [5] - The lawsuit asserts that Walgreens' public statements were materially false and misleading, leading to investor damages when the truth was revealed [5]

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and unlawful conduct regarding prescription medication dispensing [1][3][4] Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Klein v. Walgreens Boots Alliance, Inc., and covers stock purchases made between April 2, 2020, and January 16, 2025 [1] - Investors have until March 31, 2025, to seek appointment as lead plaintiff in the lawsuit [1] Allegations Against Walgreens - The lawsuit alleges that Walgreens made false statements and failed to disclose ongoing violations of federal laws related to prescription medication [3] - Specific allegations include the dispensing of unlawful prescriptions and seeking reimbursement from federal health care programs, which led to a significant drop in stock price following the announcement of a civil complaint by the U.S. Department of Justice [4] Impact on Stock Price - Following the DOJ's announcement on January 17, 2025, Walgreens' stock price fell by more than 12% over two trading sessions [4] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Walgreens stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in the last four years [6]

The Chicagoland-based companies team up to offer on-demand delivery of thousands of everyday essentials CHICAGO and DEERFIELD, Ill., Feb. 20, 2025 /PRNewswire/ -- Grubhub announced today that it has teamed up with Walgreens to bring Walgreens and Duane Reade locations nationwide to its marketplace. Through this collaboration, customers have access to 15,000 items for on-demand delivery — including beauty, health and wellness, snacks, personal care, household items, toys, and more.Grubhub is enhancing the cu ...

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/?id=130535&from=4CLASS P ...

Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for allegedly misleading investors regarding its distribution of opioid prescriptions and failing to comply with federal regulations [1][2]. Allegations - The lawsuit claims that Walgreens engaged in widespread violations of federal law concerning prescription medication dispensation and reimbursement, despite its stated commitment to regulatory compliance [2]. - It is alleged that Walgreens' revenues from prescription medications were unsustainable due to unlawful conduct, which could lead to increased regulatory scrutiny and civil liability [2]. DOJ Complaint - On January 17, 2025, the Department of Justice (DOJ) filed a civil complaint against Walgreens, alleging that the company knowingly filled millions of illegitimate prescriptions for controlled substances, including excessive quantities of opioids [3]. - The complaint states that Walgreens was aware of its responsibility to maintain compliance and that its business practices contradicted previous commitments to uphold regulatory measures [3]. - Following the DOJ's announcement, Walgreens' stock price dropped by $1.56 per share, a decline of 12.06%, closing at $11.37 per share on January 21, 2025 [3]. Class Action Participation - Shareholders of Walgreens Boots Alliance, Inc. may be eligible to participate in the class action lawsuit, with options to serve as lead plaintiff or remain an absent class member [4].